ImmuPharma (LON:IMM) Trading Up 28.8% - Should You Buy?

Key Points

• ImmuPharma's share price surged by 28.8% to GBX 13.98 ($0.19) from its previous close of GBX 10.85 ($0.15), with trading volume significantly increasing by 451% compared to the average daily volume.
• The company has a market capitalization of £69.86 million and a negative PE ratio of -1,570.67, indicating ongoing financial challenges despite a high net margin of 3,519.56%.
• ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics, including its lead program, P140 (Lupuzor™), aimed at treating autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report) shot up 28.8% on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares traded hands during mid-day trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Trading Up 28.8%

The company has a market capitalization of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The business's fifty day moving average is GBX 3.12 and its two-hundred day moving average is GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.